scholarly journals Impact of plasma glucose level and duration of type 2 diabetes mellitus on SYNTAX score II among non-ST elevation myocardial infarction patients

2021 ◽  
Vol 73 ◽  
pp. S3
Author(s):  
Soumendu Biswas ◽  
Anindya Mukherjee ◽  
Dibbendhu Khanra ◽  
Ranjan Kumar Sharma
2020 ◽  
pp. 10-11
Author(s):  
Ravindra Kumar Das ◽  
Rahul Kumar Sinha ◽  
Debarshi Jana

Background: Type 2 diabetes mellitus (DM) is a progressive chronic disorder and sustained control of plasma glucose is essential to prevent complications. Pioglitazoneofthiazolidinedionesand sitagliptin of Dipeptidyl peptidase-4 inhibitors (DPP4I) have recently been used as add-on therapy to control type 2 DM. The aim of this study was to compare the plasma glucose and glycocelatedHb% level of both the group who had poor glycemic control with Metformin and sulfonylurea. MATERIAL AND METHODS: In this observational cohort study, 100 patients with uncontrolled type 2 DM on 2000 mg/day of Metformin and 4 mg/day of Glimepiride were enrolled. The patients were randomly allocated into two groups with fifty each. One group received two divided doses of pioglitazone (30 mg/day) and the other received two divided doses of sitagliptin (100 mg/day) as the third medication. Plasma glucose fasting and 2 hours after drug and meal along with HbA1c were assessed before and after three months of treatment. Results: Fasting plasma glucose level in the sitagliptin group was higher than the pioglitazone group; however, this difference was not statistically significant (130.30 ± 30.29 versus 124.58 ± 46.84, p=0.212). Significantdifferences were not observed in HbA1c (7.20±0.96 versus 7.43±0.99, p=0.563) and plasma glucose 2 hours after meal (194.56±66.22 versus 198.58±51.5, p=0.946) after treatment withsitagliptin and pioglitazone among the two groups. Mean weight in the sitagliptin group was lower compared to the pioglitazone group after treatment, however, this difference was not statistically significant (p=0.824). Conclusion: Both the molecule as third agent had similar efficacy in glycemic control. Sitagliptin is better choice to add-on therapy in obese overweight patients.


Angiology ◽  
2015 ◽  
Vol 67 (4) ◽  
pp. 384-390 ◽  
Author(s):  
Süleyman Karakoyun ◽  
Tayyar Gökdeniz ◽  
Mustafa Ozan Gürsoy ◽  
İbrahim Rencüzoğulları ◽  
Yavuz Karabağ ◽  
...  

2017 ◽  
Vol 1 (6) ◽  
Author(s):  
Grace Puspasari ◽  
Drupadi Dillon ◽  
Budiman Budiman

The aim of the study was to investigate  the effect of daily intake of 100 grams tempe for four weeks on plasma glucose level in elderly patients with type 2 diabetes mellitus. This study was a parallel randomized clinical trial. Subjects were 30 diabetic elderly living in four nursing homes in Jakarta. In the study subjects were assigned to two groups using block randomization. All subjects had to take diabetic regiment with calorie and macronutrient following diabetic recommendation diet. The treatment group (n=16) received tempe, while control group (n=14) received legumes other than tempe. Fasting plasma glucose level (FPG) was assessed before and after intervention. Unpaired t test and Mann Whitney were used to analyzed data with the 5% significance level. There were 27 subjects completed the study: 15 of treatment group and 12 of control group. Both group were comparable in age, gender, BMI, calorie and macronutrient intake before treatment. Fat, fiber, and isoflavone intake were significantly higher in treatment group compare to control group. Decrease in FPG after intervention were observed but were statisticaly insignificant. In conclusion daily intake of 100 grams tempe for four weeks did not decrease FPG.  Keywords: elderly, plasma glucose level, tempe, type 2 diabetes


Kardiologiia ◽  
2015 ◽  
Vol 11_2015 ◽  
pp. 24-30 ◽  
Author(s):  
V.N. Karetnikova Karetnikova ◽  
M.V. Evseeva Evseeva ◽  
M.V. Zykov Zykov ◽  
I.S. Bykova Bykova ◽  
V.V. Kalaeva Kalaeva ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document